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Abstract
Intensive monitoring can be a valuable tool in the early detection of adverse drug
reactions, especially of new drugs. Aim of this pilot study was to investigate the
practical possibilities of a system of intensive monitoring, using the pharmacy
computer system to detect the first dispensing of a new drug.
Methods
Eight pharmacists were asked to monitor, using their computer system, when a
general practitioner prescribed the target drug (rofecoxib). The pharmacists were
also requested to provide the researchers at Lareb with an overview of the patient’s
medication history. Subsequently, the pharmacist sent the prescribing physician an
envelope containing information about the project and a reporting form (all
provided by Lareb), which the GP was requested to return to Lareb after the next
visit of the patient. The items on the questionnaire concerned characteristics of the
patient (anonymous), indication, dose and information about possible adverse drug
reactions. 
Results
During a four-week period the participating pharmacists signalled 44 first
prescriptions of rofecoxib. For each of these signals the pharmacist provided Lareb
with the medication history of the patient involved. Of the prescribing GPs who had
been sent the report form 70,5% (n=31) returned the form. Twenty-one of the 31
forms were returned within four weeks. The medication histories showed that in 43
of the 44 cases the dispensing of the target drug was indeed the first delivery.
The participating pharmacists and GPs were also sent an evaluation form. All
pharmacists returned their evaluations, indicating an overall motivation to
participate in the proposed system. In total seven GPs returned their evaluation
forms, three of whom had not reported adverse drug events to the national
spontaneous reporting centre before.
Conclusion
Although the number of participants in this trial was small, we conclude that
pharmacists and prescribing physicians are able and willing to contribute to an
intensive monitoring system for new drugs.
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4.1.1 Introduction
Once a drug has been approved for marketing, the use of the drug attains the
character of research in daily practice.(1) The facts about the drug that are known
at that stage are limited in that they are based on research of a restricted population,
a sample, moreover, that differs from the general population that will be using the
new drug. This emphasises the importance of close and careful monitoring of the
drug immediately following its introduction and the need for any unwanted adverse
events to be detected at the earliest possible stage. Pharmacovigilance is the science
dedicated to this monitoring process. Drugs monitoring is predominantly based on
reports of suspected adverse drug reactions from medical doctors (GPs) and
pharmacists, the so-called spontaneous reporting system (SRS), for which purpose
most countries have established national reporting centres.(2) The number of
reports submitted during the initial period following the introduction of a new drug
is reflected by a distinctive curve, first described by Weber and later adapted by
others(3,4,5). This curve is characterised by a slow rise, reaching its peak near the
end of the second year, followed by a slow, gradual drop to a lower, more or less
constant decreasing value. This implies that in the early stages after a drug has been
released little information is available from clinical practice. However, it is essential
that any negative effects of new drugs are identified as quickly as possible in order
to prevent harm to patients. This has become all the more crucial since increasingly
new drugs are developed that have a powerful impact on the human physiology.
Moreover, the registration procedure for drugs targeting illnesses for which no
adequate therapy is available has recently been shortened.
In this chapter we describe a pilot study in which we tested a detection method
specifically aimed at this first stage after the introduction of a drug that will allow
us to obtain an expedited first impression of possible unknown adverse events. The
method involves Intensive Monitoring, and makes use of the data pharmacists
collect regarding the first prescription and dispensing of a newly approved drug.
Intensive Monitoring  is a prospective observation-based cohort study investigating
a specifically selected (new) drug.(6,7) New Zealand has the most comprehensive
set of data on the practical implementation of the method because in this country
an Intensive Medicines Monitoring Programme (IMMP) supplementing the
spontaneous reporting system has been operational since 1977. The IMMP is a
constituent component of the Dunedin-based Centre for Adverse Reaction
Monitoring (CARM), which independent organisation runs the SRS on behalf of
the New-Zealand Department of Public Health.(6,8) The IMMS makes use of a
permanent cohort of approximately 10,000 drug users. The prescription data are
derived from the prescriptions dispensing pharmacists and hospital pharmacists
receive and report. Within two months the IMMS sends the prescriber a
questionnaire. 
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In the United Kingdom another form of Intensive Monitoring, the so-called
Prescription Event Monitoring (PEM) has been in existence since 1980.(9,10) This
system makes use of the prescriptions clinicians submit to the Prescription Pricing
Authority. This allows the Drug Safety Research Unit (DSRU) to collect cohorts of
20 to 30,000 prescriptions of the drugs under investigation and it sends the
prescribing physicians questionnaires, so-called green forms, three to twelve
months after the date of the first prescription. The Southampton-based DSRU is an
independent organisation founded to complement the SRS.(11)
Both in New Zealand and in the United Kingdom there is an interval of several
months between the moment the monitoring of a drug is has started until the
moment the first data of the Intensive Monitoring become available. We have tried
to devise a fast method that would cause the pharmacist, the prescribing clinician
and the national reporting system as little inconvenience as possible. The aim of the
present pilot study was to explore the possibility to expedite this process by making
use of the first delivery signals from pharmacies allowing the moment when data on
newly released drugs become available to be brought forward. 
4.1.2 Method
For the duration of one month in the spring of 2001 seven pharmacists, of whom
one was associated with two separate pharmacies, were requested to signal when a
patient was prescribed rofecoxib, the drug selected for this pilot study, for the first
time. Two weeks after delivery of the drug the pharmacist sent the prescribing
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Figure 1
Organogram of the flow of information
general practitioner (GP) a questionnaire. In addition, he or she sent the
Netherlands Pharmacovigilance Centre Lareb, the Dutch spontaneous reporting
centre, an anonymous overview of the medication history of the patient involved.
Together with the questionnaire the GP received written instructions and was
requested to forward the completed form to Lareb. The information flow between
the three parties is depicted in Figure 1. 
The pharmacists were all participants in a project analysing pharmacy data
conducted by the department of Social Pharmacy and Pharmacoepidemiology of
the Groningen University in the Netherlands. The pharmacies’ computer systems
automatically generated the signal indicating a first delivery. 
This pilot study exclusively monitored prescriptions written out by GPs. The
questionnaires the GPs received were perforated allowing the details of the patients
to be removed before the form was submitted to Lareb. The form the GPs were
asked to return consisted of a slightly moderated version of the standardised form
in use at Lareb in that it did not include the medication history since this
information was already  provided by the participating pharmacists. The
questionnaire was marked with the same code as the medication history. To
guarantee that the researchers were blind to the identity of the GPs, the return
envelopes were opened by secretarial staff that provided the form with a separate
code.
The pharmacists and GPs made use of standard return envelopes, which ensured
that at Lareb the forms submitted were processed according to the usual procedure
for reports on ADRs.
Since with this pilot study we intended to test a potential method for intensive
monitoring and not the drug, the choice of drug was of minor importance. We
opted for rofecoxib, which drug had been released on the Dutch market six months
prior to the trial. It was deemed suitable for this trial because it was a new drug that
was being prescribed regularly, also by GPs. At the time of the study rofecoxib was
solely indicated for symptomatic treatment of arthrosis. 
After conclusion of the trial Lareb requested the participating pharmacists and GPs
to fill in an evaluation form. 
4.1.3 Results
In total Lareb received 44 medication histories from the eight pharmacies (seven
pharmacists) participating in the trial. The GPs returned a total of 31 report forms,
which implies that 70.5% of the forms the pharmacists forwarded to the GPs were
submitted to Lareb. All the forms had been completed legibly and in full. On
inquiry it appeared that in three instances in which the GP had prescribed rofecoxib
for the first time, the pharmacist had not included the case in the trial. One case was
not included because the prescriber and patient were one and the same person and
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in the two other cases the pharmacist involved had mistakenly omitted inclusion. 
In 19 of the 31 submitted reports the GP had seen the patient again and in 2 cases
an adverse event was reported, both relating to gastric complaints. In one case the
patient involved had been prescribed rofecoxib before.  
Since we were interested in finding out whether it was possible to speed up the data
collection process of newly marketed drugs, we compared the date the selected
drug was prescribed with the date the report forms were received by Lareb. With
the exception of one report all forms had been submitted within six weeks after the
drug had been dispensed. 
Although outside the scope of this trial, the medication histories and report forms
Lareb received did provide some insight into the prescription behaviour and use of
rofecoxib (e.g. the patients’ age and gender and dose prescribed) in the clinical
practice. From the 44 medication histories it was derived that, apart form one case,
the recommended initial dose  for elderly patients (12,5 mg)  was not adhered to and
a dose of 25 mg had been prescribed in 43 cases. The 31 forms returned by the GPs,
however, showed that 16 of the 31 patients had been above the age of 60. This
discrepancy might be explained by the fact that health insurance companies in the
Netherlands only provide full coverage for a 25-mg dose. Moreover, in the case of
a first delivery, compensation is restricted to a maximum of 15 days, which held for
37 of the 44 prescriptions. Eleven of the 31 forms stated arthrosis as the indication. 
All participating pharmacists completed the evaluation form. The most frequent
remarks made concerned practical matters such as the return envelopes – the two
separate envelopes for the prescribing GP and Lareb – which were too much alike. 
In all cases pharmacists and GPs had been in contact to discuss the trial. Two
pharmacists had reservations about cooperating in the proposed method of
Intensive Monitoring on a long-term basis. For one pharmacist this was due to
practical reasons (discontinuation of his association with the pharmacy), and the
second pharmacist indicated not to be able to provide an unequivocal response.
Two pharmacists expressed their doubts as to whether GPs would be prepared to
make a long-term commitment to the proposed system.  
The GPs were requested to return their evaluation forms via their pharmacist to
prevent their identity from becoming known to the researchers. In total Lareb
received seven completed forms. A remarkable finding was that three of these
originated from GPs who had not reported adverse drug events to the national
reporting centre Lareb before. Six GPs recognised the potential of the proposed
drug monitoring system. One GP had reservations and mentioned time required
for the method and lack of financial compensation as prohibitive. 
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4.1.4 Discussion
Cooperation of pharmacists and physicians
The main outcome of this pilot study is that a system of Intensive Monitoring is
feasible, allowing information about the effects of newly released drugs in daily
practice to become available at an early stage. Pharmacists and GPs are willing and
have the capability to cooperate in such a system. The pharmacist has a pivotal role
in the proposed system, both with respect to signalling a drug’s first delivery and
submission of the medication history to the national spontaneous reporting system,
as well as forwarding the report questionnaire to the prescribing GP. The eight
pharmacies participating in this trial used three different computer systems. All
three systems proved to have the facility to generate a first delivery signal. In one
instance only, this function could be linked to an electronic agenda, which could
automatically generate a reminder indicating the date for the GP forms to be sent
out. Although the number of participants in this pilot study was limited, it can be
concluded that the contribution and cooperation of the GPs and pharmacists was
quite satisfactory. It needs to be noted that the pharmacists involved were all
experienced in participating in scientific research. An earlier study found that,
overall, pharmacists in the Netherlands are motivated to play an active role in
pharmacovigilance.(12)
If the number of pharmacists and clinicians were to be extended, apart from early
detection of adverse drug reactions, the system would also lend itself for more
elaborate research on drug-related aspects. Thus, insight may be gained regarding
the market penetration of a new drug, the indication for which it is prescribed and
user characteristics such as age and gender. In addition, because the system provides
data on both the user population and the use of the drug, Intensive Monitoring is,
in principle, also suitable for quantitative analyses.
This pilot study investigated the use of the system in primary health care. It is also
feasible for dispensing pharmacists to generate first deliveries prescribed by
specialists in a similar fashion. Patients that have been admitted to hospital get their
medication from the hospital’s in-house pharmacy. The response is likely to be
lower since it is known that, compared to GPs, medical specialists are less willing
to cooperate in a reporting system. (13) Examples of Intensive Monitoring in a
clinical setting have been described earlier, for instance in the USA.(14) 
Comparison with existing Intensive Monitoring systems
The system proposed in the present study distinguishes itself from the methods of
Intensive Monitoring operative in New Zealand and the United Kingdom with
respect to several aspects. 
Firstly, the system we tested makes information about a newly introduced drug
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available more quickly. Figure 2 shows schematic the different curves of number of
reports related to time. All three systems have a period of time between the
introduction of a drug and the decision to start the Intensive Monitoring. 
When this decision is made, in our system there is only a short time needed to
inform pharmacists to provide the first delivery signal and to send the reporting
form to the prescribing physician. The existing systems need more time to get the
wanted information. Of course there need to be a sufficient number of prescription
of the drug under investigation in order to get enough reports, however in our
opinion the quality of the reports adds more the outcome of reporting systems as
the number of reports does.(15)
Secondly, the method with which the data are collected is considerably less
complicated and more cost-effective than its counterparts in New Zealand and the
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Figure 2 
Schematic curves of number of reports in relation to time for different ADR
reporting systems
PBIM: Pharmacy-based Intensive Monitoring
TIM: Traditional Intensive Monitoring










UK since the proposed reporting system closely resembles the reporting methods
pharmacists and GPs are already familiar with. There is no need for a separate
administrative system to collect the prescriptions and to receive the wanted
information from the prescribing physician.
The burden on the pharmacist is higher than in the two existing systems and less
taxing for the GP because a number of details can be derived from the medication
history that is provided by the pharmacist. However, this additional task it not
likely to be prohibitive since pharmacists in the Netherlands generally already
regard reporting as an integral part of their task in providing pharmaceutical care. 
In terms of efficiency, the national pharmacovigilance centre has much to gain from
this system. The spontaneous reporting system receives these reports much like
other reports and can include them in the standard processing procedure by simply
labelling the reports as originating from Intensive Monitoring. There is one
drawback in that all first deliveries need to be recorded, whereas only a small
percentage will lead to the GP reporting an adverse reaction. This implies that the
capacity of the reporting system will possibly need to be expanded, although an
automated data exchange will keep this to a minimum. 
A noteworthy detail in this context is that Intensive Monitoring has predominantly
received the attention of pharmacovigilance centres that work independently from
the approval authorities. This applies to both New Zealand and the United
Kingdom as well as to the Netherlands Pharmacovigilance Centre Lareb. 
Possible future developments
Large-scale application of the presented system appears possible. The Netherlands
has 1200 pharmacies and with ten first deliveries of a drug under investigation the
burden will be limited while at the same time data about well over 10,000 deliveries
can be obtained. Nevertheless, a comprehensive implementation of such a system
will have its limitations. 
Whereas pharmacists appear to be motivated to contribute to Intensive Monitoring,
whether this will also hold for GPs and other clinicians when the system is applied
on a national scale is uncertain. In general, the existing spontaneous reporting
systems depend on a select, motivated group of physicians; many practising
clinicians do not contribute to the system.(11) Our trial was restricted to GPs and
earlier experiences in research involving medical specialists did not look promising.
Their reluctance to participate may lie in the fact that a monitoring system requires
their personal cooperation whereas in the case of pharmacists use can be made of
the pharmacy’s computer system and infrastructure. 
Further development of the proposed method and integration of the computer
systems of pharmacies and GP surgeries – steps towards which are currently being
undertaken in the Netherlands – will facilitate the electronic exchange and
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processing of the various data thereby considerably reducing the burden to
pharmacists and doctors as well as the national reporting system. In this way the
GP merely needs to report the suspected adverse event and the subsequent
additional information required will be automatically provided, matched and
transferred.
Additional remarks
Post Marketing Surveillance is especially needed to detect type B adverse drug
reactions and in a lesser extend type A reactions.(16) Type B reactions have a
suggestive time relationship, but will not always be detected in the few weeks
between the prescription and the moment the prescribing physician fill in the
reporting form. In the present trial the prescribing physicians were only asked to
fill in a form once, which they returned to Lareb within four weeks. This speed is
essential for a system aimed at a prompt detection of signals of as yet unknown
adverse drug reactions. The system may be extended by sending out a second form
after for instance three months, thus allowing information about drug reactions to
be gathered in the longer term.
In our system the pharmacovigilance centre receives all the information needed,
also the concomitant medication. This gives also the possibility to detect
interactions.
An important positive side effect of implementation of the proposed system
deserves special mention. Application of the method will actively involve doctors
and pharmacists in the much-needed process of pharmacovigilance. Of the seven
GPs who submitted their evaluation to Lareb three had not reported an adverse
reaction before. In other countries findings also indicate that Intensive Monitoring
may induce spontaneous reporting of suspected adverse reactions to drugs.
4.1.5 Conclusion
It is vital that after introduction of a drug information about possible associated
adverse effects can be obtained as soon as possible. The existing monitoring
methods are not designed for this purpose. The method for Intensive Monitoring
proposed in this article, which makes use of the first delivery signals from
pharmacists, was designed to fill this gap and a first, tentative trial found it to be a
fast and efficient approach. Both pharmacists and GPs willingly cooperated and
proved to be able to contribute actively in this new system facilitating the intensive
monitoring of new drugs.
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Abstract
Aim of the study
The aim of the present study was to investigate whether the concerns patients express
to a Drug Information Line about possible adverse drug reactions (ADRs) they have
experienced, are sufficiently reflected by the ADR reports submitted by pharmacists
to the Netherlands Pharmacovigilance Centre Lareb with regard to the type of
ADRs and the drug groups involved.
Methods
ADR-related questions patients addressed to the Dutch Drugs Information Line
were compared with the ADR reports pharmacists sent in to Lareb in the same
period. The similarities and differences between the two datasets as the
characteristics of the suspected ADRs and the kinds of drugs mentioned were
investigated, as well as the severity of the reported ADRs. To compare the two data
sets and to establish whether significant differences were present, a logistic regression
analysis was conducted on the reported drugs and ADRs.
Results
Analysis of the content of the phone calls yielded 1168 (14.6%) calls concerning
possible experienced ADRs. The suspected ADRs pharmacists reported to the
Netherlands Pharmacovigilance Centre Lareb in the same period included 1,734
reports. There were only slight differences between the queries patients put to the
Drug Information Line regarding possible adverse drug reactions and the reports on
suspected ADRs pharmacists submitted to the pharmacovigilance centre. With
respect to possible ADRs in the psychiatric spectrum and ADRs associated with the
use of antidepressants, there seems to be a deficiency in the reporting by pharmacists.
Conclusion
The ADRs pharmacists report to the national pharmacovigilance centre reflect




Patients are sometimes concerned about the drugs they take and prove to have a
great number of questions about these drugs.(1) It goes without saying that they
can address these questions to the prescribing doctor or the dispensing pharmacist
to have them look into their queries. However, patients in the Netherlands have
also the opportunity to put their questions regarding medication to the national
Drugs Information Line (DIL), an initiative of the Royal Dutch Association for the
Advancement of Pharmacy (KNMP).(2) This information line is open during office
hours; 150 pharmacists provide this service on a voluntary basis. A summary of
each telephone conversation is stored in a database. The DIL first became
operational in 1990 and at present approximately 10,000 questions are dealt with. 
The Netherlands Pharmacovigilance Centre Lareb is the national centre to which
doctors and pharmacist’s report suspected adverse drug reactions (ADRs).(3) 
A substantial part (40%) of the number of reports Lareb receives is submitted by
pharmacists.(4) This is not surprising since the Dutch pharmacists have made the
monitoring of the use of medication and pharmacovigilance one of their priorities
in the context of the pharmaceutical care they provide.(5-7)
In recent years there has been an ongoing debate about the potential contribution
direct consumer reporting of possible ADRs might have for pharmacovigilance.(7,8)
One of the arguments in supporting patient’s reporting system is that reporting by
patients could help solve the current underreporting of ADRs. Other considerations
that have been mentioned concern claims that through consumer reports adverse
events may possibly be detected earlier or that adverse reactions may be brought
forward that might otherwise escape the attention of health professionals.(9,10) 
Observations and reports made by health professionals generally are a combination
of an interpretation of a description originally provided by the patient and objective
information.(11)
In an earlier study regarding the Drug Information Line, Van der Toom and
colleagues studied the question to the DIL during three short periods.(12) Egberts
and colleagues compared information derived from the DIL database with data
from physicians and pharmacists in the Lareb database and evaluated patient
characteristics and the drugs involved.(13) 
In the present study we compared the ADR-related questions patients put to the
Drugs Information Line with the ADR reports pharmacists sent in to Lareb in the
same period. More specifically, similarities and differences between the
characteristics of the suspected ADRs and the kinds of drugs mentioned were
investigated. The aim of the study is to establish whether the reports of pharmacists




In our study we compare two datasets: one of questions to the Drugs Information
Line and one of pharmacist’s reports to the Netherlands Pharmacovigilance Centre
Lareb regarding drugs and ADRs. The study covered the period between 1 January
1998 and 15 March 1999 and, given that both the Drugs Information Line and
Lareb work on a national scale, entailed a nationwide comparison. The entire range
of questions the DIL processed during this period was analysed and coded by an
experienced assessor. The questions related to possible experienced adverse events
were selected and subsequently categorised for further analysis. Only those
questions with the following criteria were included in the analyses: the suspected
drug could be identified, the adverse drug reaction had been experienced by the
caller him/herself and the caller’s sex was known. Enquiries about possible ADRs
and calls with too general complaints were excluded.
The ADRs mentioned by the various patients were assigned a so-called WHO
preferred term. Subsequently, each preferred term was assigned to one System
Organ Class (SOC), i.e. a group of preferred terms pertaining to the same organ
system.(14) The drug concerned was coded according to the first position of the
Anatomical Therapeutical Chemical system (ATC-system).(15)
Similarly, all the reports of suspected ADRs Lareb received from pharmacists
during the period under investigation were selected and subsequently coded using
the procedure described above. 
To compare the two data sets and to establish whether significant differences were
present, a logistic regression analysis was conducted on the reported SOCs and
ATC codes. The odds ratios, (ORs) adjusted for age and gender, of the various
SOCs and ATCs as reported by patients (DIL) and pharmacists (Lareb) were
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Table 1
Number of questions (DIL) and reports (Lareb), ADR-related questions and
reports, included cases, suspected drugs and reported adverse drug reactions from the
Drug Information Line and from the pharmacist reports submitted to Lareb (1/1/98
– 15/3/99)
DIL Lareb
Total number of questions DIL and pharmacists reports 
to Lareb 8340 1734
Number of questionsabout experienced ADRs 1168 1734
Number of included cases 1041 1734
Number of suspected drugs 1041 1814
Number of reported adverse drug reactions 1323 2426
calculated as well as the corresponding 95%-confidence intervals. For the statistical
analysis SPSS 10.0 was used.
Next, for both groups the proportion of possible serious reports was estimated. For
this procedure we applied the criteria for ‘critical term’ as defined by the WHO.(16)
Critical terms are a subset of the WHO preferred terms indicative of serious disease
states that warrant follow up. For this reason critical terms may be of particular
interest for signal generation. 
4.2.3 Results
In the study period the suspected ADRs pharmacists reported to the Netherlands
Pharmacovigilance Centre Lareb that were included in our study totalled 1734 reports,
of which 595 concerned men (34.3%) and 1139 women (65.7%). In the same period
the DIL processed 8012 queries by patients. Analysis of the content of the calls yielded
1168 (14.0%) calls concerning possible or suspected ADRs experienced by the caller
themselves. In total, 1041 of the 1168 cases (12.5% of the total number of calls) could
be included because ADR, suspected drug and sex of the patient were known. Of these
cases, 299 involved men (28.7%) and 742 women (71.3%). The number of included
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Table 2
Distribution of drugs according to ATC main group of reported ADRs of the Drug
Information Line (n=1041) and pharmacists’ reports to the Netherlands
Pharmacovigilance Centre Lareb (n=1814).
Code ATC main group DIL Lareb Odds 95% conf. int.
A Alimentary tract and metabolism 50 142 1.68 1.21-2.34
B Blood and blood forming organs 33 55 0.94 0.61-1.46
C Cardiovascular system 182 453 1.55 1.28-1.88
D Dermatologicals 18 47 1.49 0.86-2.59
G Genito-urinary system and sex hormones 83 118 0.83 0.62-1.11
H Systemic hormonal preparations 42 34 0.46 0.29-0.74
J General anti-infectives for systemic use 45 222 3.05 2.19-4.24
L Antineoplastics and immunomodulants 15 32 1.22 0.66-2.27
M Musculo-skeletal system 49 134 1.65 1.18-2.31
N Central nervous system 462 339 0.29 0.24-0.34
P Antiparasitic products 6 38 3.64 1.53-8.65
R Respiratory system 46 138 1.77 1.26-2.50
S Sensory organs 6 28 2.79 1.15-6.77
Only those System Organ Classes that have more than 5 cases are included in this table.
The Odds is adjusted for age and gender.
suspected drugs and reported ADRs to Lareb by pharmacists and those reported from
the Drug Information Line are shown in Table 1. The differentiation in the drugs
involved, as reported by pharmacists (Lareb) and by patients (DIL) can be found in
Table 2. The differences in the reported ADRs as coded per SOC for both groups are
shown in Table 3.
drug categories
Looking at the drug categories, we observed that the number of reports from
pharmacists to Lareb was significantly higher for medication directed at treatment
of disorders in the alimentary tract and metabolism, cardiovascular system,
antibiotics, musculo-skeletal system and respiratory system (Table 2). By contrast,
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Table 3
Distribution of System Organ Classes for ADRs reported by patients to the Drug
Information Line (n=1223) and for ADRs reported by pharmacists to the
Netherlands Pharmacovigilance Centre Lareb (n=2426).
Code System Organ Class DIL Lareb Odds 95% conf.
int.
100 skin and appendages disorders 86 369 2.60 2.04-3.32
200 musculo-skeletal system disorders 53 119 1.21 0.87-1,68
410 central and peripheral nervous system d. 181 337 1.03 0.85-1.25
431 vision disorders 44 103 1.28 0.90-1.84
432 hearing and vestibular disorders 9 19 1.12 0.50-2.49
433 special senses other disorders 18 67 2.20 1.19-3.42
500 psychiatric disorders 220 230 0.50 0.42-0.63
600 gastro-intestinal system disorders 215 414 1.07 0.90-1.29
800 metabolic and nutritional disorders 44 32 0.38 0.24-0.61
900 endocrine disorders 8 11 0.69 0.28-1.74
1010 cardiovascular disorders – general 11 18 0.90 0.43-1.92
1030 heart rate and rhythm disorders 29 57 1.05 0.67-1.65
1040 vascular (extracardiac) disorders 11 28 1.39 0.69-2.80
1100 respiratory system disorders 38 131 1.92 1.33-2.78
1230 platelet, bleeding & clotting disorders 16 50 1.67 0.95-2.95
1300 urinary system disorders 9 31 1.88 0.89-3.96
1410 reproductive disorders, male 18 11 0.27 0.13-0.58
1420 reproductive disorders, female 40 54 0.80 0.54-1.21
1810 body as a whole – general disorders 243 288 0.60 0.50-0.73
Only those System Organ Classes that have more than 5 cases are included in this table.
The Odds is adjusted for age and gender.
the DIL answered significantly more questions about hormone-based medication
(excluding sex hormones) and drugs affecting the nervous system.
adverse drug reactions
The number of questions that the DIL received about adverse drug reactions was
higher for the following SOCs: psychiatric disorders, male reproductive disorders
and also for autonomic nervous system disorders (significant, but low numbers) –
see Table 3.
The ADRs for which Lareb received a higher number of reports from pharmacists
involved the following SOCs: ‘Skin’, ‘Special Senses’ and ‘Respiratory System’.
severity of the suspected ADR
Regarding the severity of the suspected ADR, as expressed by the number of
reports that met the criteria for ‘critical term‘, we found that of the Lareb reports
264 out of 1223 (11.9%) met this standard and this was 91 (7.4%) for the questions
posted to the DIL. Thus, the number of reports on serious ADRs was statistically
significantly higher for the pharmacists report to Lareb: OR 1.58 (95% confidence
interval: 1.23 – 2.02).
4.2.4 Discussion
The findings of our study show that there are only slight differences between the
reports on suspected ADRs pharmacists submitted to our pharmacovigilance centre
and the queries patients put to the Drug Information Line regarding possible ADRs. 
The majority of the patients reported on by the pharmacists to Lareb and the callers
to the DIL, was female. This should be seen in the light of the greater medical
consumption by women and their concomitant higher use of medication.(17) 
The need for more information about the drugs being taken and in particular details
regarding possible ADRs is evident. We included only those questions that
concerned possible ADRs the patients had experienced themselves that could be
coded as a WHO preferred term and of which the suspected drug was known
(14.0%). This explains the difference with the study by Van der Toom et al. and
Egberts et al. who found that respectively 21.6 and 28% of the callers’ queries
concerned adverse events.(12,13) 
Although the difference between the ADRs pharmacists reported to Lareb and the
complaints the DIL received was significant for the SOCs autonomic nervous
system disorders and male reproductive disorders, the numbers involved were
small. This also applies to the SOC metabolic and nutritional disorders mainly
associated with obesity. For both these categories of questions holds that the caller
seems to appreciate the anonymity of the DIL. 
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Many callers mentioned possible ADRs related to psychiatric disorders. This is not
exceptional since a considerable proportion of the reports Lareb receives also falls
into this category. Apparently, questions relating to these subjects are not as easily
put to the pharmacist, which prevents patients from reporting any such adverse
effects. Patients rather turn to their doctor or, again, prefer to call an anonymous
helpdesk. It needs to be noted that an earlier study had revealed that with respect
to the SOCs male reproductive disorders and psychiatric disorders Lareb received
significantly more reports from medical practitioners than from pharmacists.(13,17)
As regards to the drugs for which adverse reactions were reported, we found that,
compared to the pharmacist reports, the number of calls to the DIL about drugs
affecting the CNS were far higher. The calls mainly concerned the largest type of
drugs of this category, i.e. antidepressants. Van der Toom et al. found also CNS
drugs as the biggest group and Egberts et al. had earlier reported a similar finding
regarding antidepressants.(12,13)
This is not surprising since the use of antidepressant drugs is still increasing. The
proportion of both adverse events of a psychiatric nature and events associated with
the use of antidepressants is higher for the DIL when compared to the number of
these ADRs in the pharmacists’ reports to Lareb. Despite the fact that pharmacists
also operate the DIL, as mentioned earlier the anonymity of the helpline seems to
play a role. The professional background of the person answering the call does not
appear to play a role in the patient’s decision to call the DIL. It is possible that for
concerns that relate to the patient’s private life, patients are more inclined to turn to
the DIL and since it is exactly this type of query that worries most users, the need
for a second opinion may be high. This fact may also explain the high incidence of
calls of this nature.
With respect to the severity of the ADRs reported we found that the proportion of
pharmacist’ reports signalling a possibly serious ADR was higher than the number
of questions about possible serious adverse drug reactions addressed to the helpline.
This seems to imply that for serious complaints patients tend to go straight to a
pharmacist.
In general, pharmacists’ reports to the Netherlands Pharmacovigilance Centre
Lareb prove to be a good reflection of the questions patients have regarding ADRs.
Pharmacists consider answering questions from patients’ part of the pharmaceutical
care they give, which function has been fully integrated in the pharmacies’
operational procedures. This should be considered in the discussion about the value
of direct ADR reporting by patients, however other and more specific reporting
facilities for patients to report possible ADRs should be taken into account in this
discussion.(8)
The organisation of a helpline is quite complex: a considerable number of volunteer
pharmacists and organisational adaptations are required to operate such a system.
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These pharmacists have also the possibility to report a possible ADR to the national
pharmacovigilance centre, which is seldom done for questions answered through
the Drug Information Line.
This study has some weaknesses. It should be taken into account that no causality
assessment has been performed. Such an assessment was not possible due to the
limited information that is obtained from callers to the DIL. This prevents
conclusions to be drawn about possible new signals of an ADR. It may be possible
that some questions to the DIL, if reported to their pharmacist, will be sorted out
because they were not considered to be a possible ADR in his of her professional
view. Reports from pharmacists to the national pharmacovigilance centre are far
more detailed in comparison with the information given to the information line.
This study should not be regarded as a comprehensive study. Of the two groups
investigated, only a limited number of factors have been compared. The Drug
Information Line is not designed for the detection of ADRs and only limited
information is available. Moreover, possible ADRs are not recorded in a
standardised way. It also needs to be noted that it was not possible to determine
how many of the questions patients put to the Drug Information Line had also been
put to their health professionals, who subsequently reported these to Lareb.
Both groups which we compared in this study involved pharmacists. The Drug
Information Line is staffed by pharmacists and only the reports pharmacists
submitted to Lareb were taken into account. Despite the fact that pharmacists are
quite willing to answer patient questions about drug use and problems in their
pharmacies, for some users the threshold seems too high. These individuals prefer
to call the DIL. This finding indicates that the role of the pharmacist, being an
expert in his/her field and thus best equipped to provide independent, professional
information in the pharmacy, should be enforced. It is also recommended that the
patient leaflet inform drug users about the fact that possible adverse drug reactions
should be notified to their health professional, physician or pharmacist. 
4.2.5 Conclusion 
Patients take a keen interest in the drugs they are taking and are frequently in search
of answers to questions concerning these drugs. A substantial part of their worries
concern possible ADRs. Although the prescribing doctor and dispensing
pharmacist are the most obvious and best-equipped persons to address these
questions to, a telephone service providing information on drugs appears to fulfil a
need. A comparison of the reports pharmacists submit to a spontaneous reporting
system with questions put to a drug information line shows that, for the aspects
investigated, the nature of ADRs as reported by pharmacists match the features of
the phone queries. However, particularly with respect to possible ADRs in the
psychiatric spectrum and suspected ADRs associated with the use of
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antidepressants, there proves to be a deficiency in the reporting by pharmacists, but
are within Lareb corrected by a higher proportion of reports from physicians.
Despite this obvious limitation, it may be concluded that, in general, the ADRs
pharmacists report to the national pharmacovigilance centre adequately reflect the
patients’ concerns about possible ADRs associated with the medication they are
taking.
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Abstract
The direct reporting of adverse drug reactions by patients is becoming an
increasingly important topic for discussion in the world of pharmacovigilance. At this
time, few countries accept consumer reports.
An overview is given of experiences with consumer reporting in various countries of
the world. The potential contribution of patients reports of adverse drug reactions is
discussed, both the qualitative and quantitative contribution. The crucial question is
one of whether patient reports will increase the number and quality of the reports
submitted and/or lead to a more timely detection of signals of possible adverse
reactions, thus contributing to an enhancement of the existing methods of drug




The direct reporting of adverse drug reactions by patients is becoming a
increasingly important topic for discussion in the world of pharmacovigilance. In
several countries there is an ongoing debate about the question or consumer reports
without physicians or pharmacists as a intermediate are desirable. In this paper we
use the term consumer reporting, however it might be argued that the word
consumer relate more to a commercial product as to a health care product. Patient
reporting could be a better term, relating it more to patients than to the producer’s
side of drugs.(1)
A key problem in the discussion about the usefulness of consumer reporting is the
fact that there is little evidence, especially when we relate consumer reporting to
spontaneous reporting. All the information available in the literature regards
research using questionnaires or using a drug information service, and is not the
results of experiences with consumer reporting to a centre that collects spontaneous
reports.(2-7)
In this overview we will make an inventory of experiences with consumer reporting
in various countries of the world. The potential contribution of patients reports of
adverse drug reactions will be discussed, both in terms of their qualitative and
quantitative contribution. 
4.3.2 The necessity of pharmacovigilance
The advent of pharmacotherapy based on recent scientific advances in the first half
of the twentieth century brought about revolutionary changes in the scope of cures
for numerous diseases. These innovations were of course enthusiastically
welcomed, and this welcome was almost without question; the negative aspects of
pharmacotherapy received little or no attention. Only when adverse reactions of a
particular drug were evident, were critical questions asked, but otherwise scrutiny
was never systematic.(8)
It was the Dutchman Meyler who, in 1951, was the first to provide a systematic
overview of ‘side effects of drugs’. His work formed the basis of what is, on an
international scale, still regarded as the standard work in the field of adverse effects
of drugs.(9)
The thalidomide tragedy in the early 1960s induced many countries to set up
national bodies to monitor the safety of drugs, also known as pharmacovigilance
centres. The underlying motive for the establishment of such national centres was
that, by giving physicians and pharmacists the opportunity to report suspected
adverse events, potential but as yet unknown side effects of drugs would be
detected at an earlier stage. It was thought that serious and extensive damage as had
been caused by thalidomide could thus be prevented. European legislation has led
to uniformity in pharmacovigilance within the European Union by stipulating
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which tasks and responsibilities are to be carried out and assumed by the national
governments, the pharmaceutical industry and the various professional groups
involved. 
Many countries, among which all EU member states, have organised their reporting
systems for potential adverse events in such a way that only physicians and
pharmacists are qualified to report.(10) In a number of countries pharmacists are
not necessarily authorised to report.(11) 
This method of collecting and analysing data from the health care sector is called a
‘spontaneous reporting system’ (SRS), the word spontaneous in this context
meaning that reporting is not compulsory. Consumer reporting was never before an
item in the organisation of SRS; it is only recently that consumer has become a point
of discussion. When we use the term consumer reporting, it is about users of drugs
reporting suspected adverse drug reactions to a spontaneous reporting system.
4.3.3 International experiences and developments concerning patient reports
To date there is little practical experience with patients reporting adverse drug
reactions. In a limited number of countries the national reporting system provides
some (formal) room for patient reports. Below we will discuss the current situation
on consumer reporting in various countries.
United States
MedWatch, the FDA’s Safety Information and Adverse Event Reporting Program,
offers patients some scope to directly report adverse drug reactions. The majority
of reports originating from patients that actually reach the FDA, however, are sent
in by the pharmaceutical industry. This sector has the legal obligation to pass on all
reports it receives. Thus, questions and complaints from patients concerning drugs
addressed to the marketing authorisation holder are categorised as patient reports.
A mere 12% of all reports the FDA receives have been directly submitted by
physicians, pharmacists or health consumers. Approximately a third of these
reports stem from patients.(12) No publications have been done yet about the
contribution of consumer reports to the FDA.
Australia
Since the early 1990s Australia has been taking its first steps towards creating
facilities allowing patients to report complaints on drugs. The Australian Patient
Safety Foundation runs and maintains the Australian Incident Monitoring System
(AIMS). However, only 20% of the reports concern medication and only 4% of
these are about adverse events. The national reporting system (ADRAC) receives
about 10,000 reports per year and this includes all appropriately documented
patient reports. On an annual basis the latter comprise fewer than 100 reports.(13)
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Scandinavian countries
In September 2000 Kilen, the Swedish Consumer Institute for Medicines and
Health, organised a conference that was announced as the ‘First International
Conference on Consumer Reports on Medicines’.(14) The key topic of the
conference was: Should patients be given the opportunity to report possible adverse
drug reactions direct to a national body? Kilen does collect patient complaints about
drugs in Sweden and Norway although these complaints specifically concern
addiction to benzodiazepines and lorazepam in particular. Thus, practical experience
with comprehensive consumer reporting is still limited and Kilen’s full objectives
have as yet not been implemented. Remarkable is the fact that in the Scandinavian
countries pharmacists are not allowed to report ADRs to their national centres.
The Netherlands
In the Netherlands there is no hands-on experience with consumer reporting
although some research into the topic has been conducted. In 1998 the
Wetenschapswinkel Geneesmiddelen (Science Shop for Drugs) of the Faculty of
Pharmacy of the University of Utrecht published a study in which it was
investigated which specific facilities would allow patients to report side effects in
the Netherlands and how these facilities could be adjusted and extended.(15)  In a
round-table conference following the project it was concluded that further research
into consumer reporting was desirable. Also, two Dutch hospitals have conducted
research into patients as information source for possible adverse events.(2) 
Recently the Dutch Consumer Association insisted on the fact the consumer
should be able to report suspected adverse drug reactions to the national
pharmacovigilance centre.
United Kingdom
In the UK the Consumers’ Association has also suggested that patients should
perhaps be offered facilities to report on adverse drug reactions.(16) Again, as in
Sweden, the late discovery of dependency on benzodiazepines was mentioned as an
example of signals that might be reported earlier by patients than professionals. 
The Medicines Control Agency (MCA) maintaining the national reporting system in
the UK has responded with caution based on both intrinsic and practical arguments.
Nevertheless, in the UK the National Health Service does facilitate the reporting of
complaints by patients, and, although the emphasis is not on drugs, adverse effects are
also mentioned in this context.(17) Recently there are new developments regarding
direct consumer reporting because of the intended merger of the Medicines Control
Agency and the Medical Devices Agency. The Medical Devices Agency accepts
patients reports and once the agencies emerge it is would be possible the new agency
also accept direct reports from consumers of pharmaceuticals.(18)
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The Internet
Novel is the emergence of web sites on the Internet offering patients a forum to
exchange their experiences with drugs. Apart from being an expression of the
patients’ need to share and exchange information about medication, the
phenomenon also shows that patients are a rich source of information. It is evident,
however, that distinguishing valuable from unreliable data on the Internet poses a
real problem.(19)
4.3.4 Potential contribution of patient reports on adverse reactions
In the debate on the advisability of offering patients facilities to report suspected
side effects of drugs, various issues play a part. These will be outlined next.
Qualitative contribution 
It is to be expected that reports from a patient perspective will cause a shift in the
type of adverse reactions being reported since the reports that now reach the
reporting systems may not reflect the adverse events that were originally reported
because of the filter applied by physicians and pharmacists.(7) With patient reports,
not only side effects that health professionals generally consider less relevant will
receive attention, but also complaints that are usually less easily communicated, for
instance those relating to sexual matters.(20) Similarly, adverse effects caused by the
off-label use of medication (applications deviating from the approved indication)
are probably less likely to be reported by doctors than by patients. In addition,
doctors may not always be familiar with certain over-the-counter drugs or
alternative medication.
Quantitative contribution
Consumer reporting will raise the number of reports submitted, which will enhance
the impact of the reporting systems. Despite the fact that research has repeatedly
shown that in the Netherlands the basis of trust between patients and their doctors
and pharmacists is such that this generally does not form a major obstacle, the fact
that less than 10% of the professionals involved effectively pass on reports does put
things in an different perspective: many complaints from patients appear to founder
on the reluctance of the health care professionals.(21) The huge number of queries
the Dutch Geneesmiddelen Info Lijn (Drug Information Line) receives suggests
that the number of reports submitted by patients may be considerable. 
Political and strategic considerations
An important consideration in support of direct reporting by patients is the fact
that, given today’s increasing patient awareness and emancipation, it is desirable
that patients are given the opportunity to report suspected side effects themselves.
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After all, it is the patient that experiences the adverse reactions, which makes him
or her the hands-on expert.
Reporting through GP or pharmacist implies that complaints are filtered out, which
prevents patient complaints from reaching the reporting system. Since patients and
consumer organisations have acquired a considerable say in determining health care
policy, perhaps this argument may carry more weight than before.
4.3.5 Possible objections to and limitations of patient reports
Consumer reporting does not seem to get off the ground properly anywhere.
Apparently, there are serious obstacles that prevent a timely establishment of
reporting systems for the collection and evaluation of adverse drug reactions
reported by patients.
Establishing the contribution of patient reports in relation to the existing signal
detection systems
The main obstacle for the development of consumer reporting systems is the
fundamental question regarding their intrinsic value. 
The existing reporting systems, primarily based on spontaneous reporting by
doctors and pharmacists and on obligatory reporting by marketing authorisation
holders, have evolved extensively over the past few decades, particularly with
respect to both the quality and the analyses of the reports. 
As far as we know, no research has been conducted to show that extending the
current systems to include reports from patients will add to their value when the
size and speed of signal generation and detection are concerned.
Quality of patient reports
A key issue concerns the quality of the reports submitted by patients. Firstly, the
quality as regards the selection of the reports is at stake: Are patients capable of
distinguishing possible adverse drug reactions from other complaints associated
with the use of medication? A second aspect relating to the quality of patient
reports is their documentation. Is a lay reporter capable of providing a clear and
objective description of the side effects and can he or she supply the relevant clinical
information necessary for an adequate evaluation of the report? 
4.3.6 Discussion
Since during the clinical trials, carried out in the evaluation and marketing
authorisation stages, the safety of drugs can only be investigated to a limited extent,
it is essential to also monitor their safety after marketing. For this purpose, many
countries have set up a national pharmacovigilance system, which, as a rule,
functions on the basis of spontaneous reporting by physicians and pharmacists. In
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this paper the advisability of direct reporting of potential adverse drug reactions by
patients was evaluated. 
It is evident that patient reports are desirable from a politico-strategic perspective.
Edwards has typified the reporting of side effects as concern reporting.(22) Apart
from the medical professionals, the users of drugs also have such concerns.
Physicians, pharmacists and patients all have reason for concern when the safety of
drugs is concerned and all parties need to be able to express their worries in such a
way that they can be assured that they are taken seriously and that the necessary
steps will be taken. The fact that patient and consumer organisations have
considerable influence on health care policy, lends validity to this argument.
Consumer reporting is in line with the striving for quality in the health care system,
in the evaluation of which the care taker takes up a key position. Unfortunately, to
date few studies into the potential contribution of patient reports on possible
adverse drug reactions are available in the literature. Both Solovitz et al. and
Mitchell et al. have reported that users of drugs are capable of discriminating
between side effects and other complaints or symptoms.(4,5) Mitchell et al. are
more hesitant in this respect, particularly in connection with the patient’s ability to
associate suspected adverse events with a particular drug. However, one may ask
whether this should be the reporter’s responsibility. In a retrospective study
Egberts et al. compared the questions posed by the users of drugs with adverse
reactions reported by physicians and pharmacists in the same period.(6) It appeared
that about a certain number of signals derived from the database of the official
reporting system users had earlier demanded information. Van de Bemt et al. have
shown that when specifically asked for them, hospital patients were able to report
on side effects.(2) In this case the reported effects mainly concerned less serious
reactions that were not known at the time. It needs to be noted, however, that it was
not investigated whether the reported adverse reactions were effectively related to
the drugs used. Jarernsiripornkul et al. reported that patients are willing to report if
they are asked to do so.(3)
Both the Netherlands and Australia have been considering whether specific patient
groups could function as reporting parties. Such a reporting system could be efficiently
organised and could specifically analyse patients’ experiences with particular groups of
drugs. In this context research into new drugs aimed at particular patient groups, e.g.
rheumatics or diabetics, could be thought of, during which study patient organisations
could also be involved. However, if reports are expressly invited, this would be a case
of Intensive Monitoring, which implies research rather than continuous surveillance. 
Establishing a system to collect patient reports is no easy matter. For instance, are
patients interested in a system specifically aimed at gathering suspected adverse
drug reactions or would they prefer a system with a wider scope covering other
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aspects of pharmacotherapy It is clear that a more comprehensive system will be
quite different from a system that focuses solely on possible side effects. Either way,
the evaluation and scientific analysis of the reports received will require manpower
and funds. A reporting system raises expectations with those who report, i.e. they
expect their reports to lead to results, and, in addition, they wish to be informed
about the steps to be taken. With reporting systems for the medical professions
such feedback has proved essential for their success (22).
Setting up a patient reporting system requires a separate organisation. The existing
doctor-pharmacist systems are hesitant in taking on this extra task. This hesitation
originates from the fear that the system will receive too much ‘noise’ without the
added value of the new system having been established, receiving many but poorly
documented reports. Again, this relates to the question whether patient reporting
systems should merely concentrate on side effects or whether they should also take
other aspects of drug use relevant to patients, such as queries regarding delivery and
use, into account.
Reporting of experienced adverse drug reactions through a health professional
could mean a kind of filtering. Also could be argued that this filter is a wished one,
preventing an overload of national pharmacovigilance centre with invalid reports.
There is some parallel with the discussion about direct-to-consumer drug
advertisements.(23) On one hand these advertisement could stimulate consumer
reporting. On the other hand in this discussion is also the question for the need of
a ‘learned intermediary’.(24) 
Apart from reports that are submitted direct to the national pharmacovigilance
centres, there are also consumer reports that are sent to the pharmaceutical
companies that produce the drugs concerned. As mentioned earlier, this latter
practice is quite common in the United States. A recent study has investigated the
way the pharmaceutical sector deals with these consumer reports (25). Most drug
companies include the information derived from such reports in their databases.
Moreover, they have the legal obligation to pass on any reliable information about
their products to the authorities. In most cases, however, the data received are
insufficient to perform a proper causality assessment.
To be able to make a well-founded judgement on the advisability of an independent
reporting system for patients the pivotal question in need of an answer is whether
such a system will add to the value of the existing systems. Such a study should be
carried out within the context of a spontaneous reporting system.
Establishing a patient system for political and strategic reasons only, without having
established its possible added value first, falls outside the scope of pharmacovigilance. 
Adverse drug reactions do not only concern patients, both the prescribing doctor and
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the delivering pharmacist are also involved. Reporting in cooperation with the
prescribing doctor and/or pharmacist seems to be preferred method of reporting,
supposing these professionals do report. The crucial question is whether patient
reports will increase the number and quality of signals of adverse drug reactions
and/or lead to a more timely detection of them, thus contributing to an enhancement
of the existing methods of drug safety monitoring. To date, the data available are
insufficient to establish such added value.
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Over the past few years, a number of drugs have been withdrawn for safety reasons,
either by drug approval authorities, or by the manufacturer. A recent example is the
withdrawal of cerivastatin in connection with rhabdomyolysis. Several other drugs
have also been taken off the market as a security measure, not because the nature of
the risk involved was unknown but because the risk had proved apparently
uncontainable. It seems that the inclusion of a warning or contraindication in the
Summary of Product Characteristics (SPC) or sending a ‘Dear Doctor’ letter is
insufficient to ensure compliant prescription behaviour. There appears to be a
discrepancy between the careful use of evidence underpinning the SPC content and
formal warnings and changes to the SPC and the effect they have on the prescription
and dispensing of the drugs involved. This results in undue loss or damage for both
the manufacturer and the patient.
There are no easy solutions to tackle this problem; the ineffectiveness of labelling and
‘Dear Doctor’ letters has ramifications for the whole regulatory/industrial/
educational complex.
We discuss briefly four possible strategies for improving the current situation,
emphasising on the place the prescriber has in this process.
The first strategy is education-based. Clinicians need to know about the comparative
merits of the effectiveness and risk of drugs, as well as how they work
pharmacologically, toxicologically, and what interactions they have with each other.
The second strategy involves improving the information available for clinicians.
Frequently, physicians do not consult the SPC for verification, leaving aside whether
they have taken notice of the contents of the official SPC in the first place. It is
recommended to that the accessibility of SPCs is enhanced for doctors and
pharmacists, drawing attention specifically to any changes. There needs to be a single
body of information that covers every drug.
The third strategy involves communication. There is much to be done in this area
both in terms of follow-up and understanding of health professional’s behaviour and
how to empower best practise.
The final strategy involves professional freedom. It goes without saying that doctors
who issue off-label prescriptions may need to justify their actions. Deviating from
the SPC should always be a considered decision and health professionals need to be
aware of the additional responsibilities associated with such a decision. The




Withdrawing a drug from the market is a drastic measure. Over the past few years
a number of drugs have been withdrawn for safety reasons, either by drug approval
authorities, or by the manufacturer. A recent example is the withdrawal of
cerivastatin in connection with rhabdomyolysis, occurring especially when
cerivastatin is prescribed in combination with gemfibrozil. What was remarkable in
this case was the fact that the Summary of Product Characteristics (SPC) did
include a warning for this interaction and also that the manufacturer had alerted the
health professionals in ‘Dear Doctor’ letters about the complication.
Several other drugs have also been taken off the market as a security measure, not
because the nature of the risk involved was unknown but because the risk had
proved apparently uncontainable. It seems that including a warning or
contraindication in the SPC or sending a ‘Dear Doctor’ letter is insufficient to
ensure compliant prescription behaviour.
4.4.2 Practice
A number of studies have been published on the effects of adjustments of the SPC
content and ‘Dear Doctor’ letters in connection with the incidence of arrhythmia
associated with the use of cisapride.(1,2) Notwithstanding the fact that in the US
four label changes and notifications had been issued, in 3.4% of the cases the
concomitant use of at least one contraindicated drug had occurred.(1) It was not
until the risks of cisapride had received more extensive media attention that the co-
dispensing of drugs that should not be taken together with cisapride actually
decreased.(2)
In March 2000, troglitazone was recalled from the market because of life-
threatening acute liver failure. The risk was known and was referred to in the SPC.
In the US the manufacturer had distributed four ‘Dear Doctor’ letters, which
included the recommendation that liver function be tested more frequently.
Although subsequently the number of patients tested increased 3-fold, a mere 5%
of users were tested in the recommended frequency after 3 months on the drug.(3) 
Recently, research results on the indications for which rofecoxib is prescribed were
published in the Netherlands.(4) Rofecoxib was originally approved in the
Netherlands for the indication ‘symptomatic treatment of arthrosis’. However,
promotional material directed at physicians particularly emphasised ‘pain relief’,
even though costs are officially only reimbursed for the indication (osteo)arthrosis.
An evaluation of the electronic data collected from the prescribing general
practitioners showed that over 80% of the prescriptions involved a different
diagnosis than that of ‘arthrosis’, thus constituting a deviation from the indication
specified in the SPC. The researchers concluded that rofecoxib is prescribed for a
wider range of indications than for which it was approved.
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The content of the SPC is compiled with due consideration of the evidence
available, including information from the clinical trials conducted prior to
marketing authorisation. The definitive text is determined by the drug approval
authorities and the SPC becomes part of the registration file. ‘Dear Doctor’ letters
are drawn up in close co-operation with the manufacturer and the drug approval
authorities. This also holds for any changes in the content of the SPC, such as
alterations resulting from postmarketing research that have led to new insights into
the safety aspects of the drug.
4.4.3 The problem
There appears to be a discrepancy between the careful use of evidence underpinning
the SPC content and formal warnings and changes to the SPC and the effect they
have on the prescription and dispensing of the drugs involved, as shown by the
cases mentioned above. If and when physicians and pharmacists do not adhere to
the SPC and their decisions lead to an increased safety risk, the decision to
withdraw a particular drug from the market may be expedited. This results in undue
loss or damage for both the manufacturer and the patient.(5) It may be argued,
therefore, that physicians and pharmacists should adhere to the indications,
warnings and contraindications as described in the SPC. Also, any alterations in the
content of the SPC should be followed up in daily practice. The same applies for
the information disseminated via ‘Dear Doctor’ letters.
Legally, however, physicians can deviate from the indications as described in the
SPC. In some cases they have no other option, as occurs for instance in paediatric
practice quite often because of lack of clinical trial information on children. In
addition, warnings and contraindications can be ignored. There can be sound
clinical reason in this. Clinical trial and epidemiological evidence can only provide
a guide as to the normal group response to a drug or other therapy. It goes without
saying that doctors who issue off-label prescriptions may be need to justify their
actions. Deviating from the SPC should always be a considered decision and health
professionals need to be aware of the additional responsibilities associated with
such a decision.
4.4.4 Possible solutions
We are aware that as we are discussing the ineffectiveness of labelling and ‘Dear
Doctor’ letters, it has ramifications for the whole regulatory/industrial/educational
complex. The complexity of this could easily hinder the necessary debate. We will
briefly discuss four possible strategies. Given that clinicians must interpret evidence
and not try to force patients into convenient algorithms, what can be done to




Drug therapy is a complex business. New drugs become available all the time, as
well as new information on old drugs. The clinician, in particular, has the role of the
‘learned intermediary’ to evaluate knowledge critically and to use and explain it in
a given individual setting. To be a ‘learned intermediary’ health professionals must
understand the drugs they use and it is important to acknowledge that
undergraduate curricula are overloaded, and only the rudiments of clinical
therapeutics can be taught. Clinicians need to know about the comparative merits
in effectiveness and risk of drugs, as well as how they work pharmacologically,
toxicologically, and how they interact with each other. Then the clinicians may
make logical inferences for the therapy of the patients they treat.
2. Information
Frequently, physicians do not consult the SPC for verification, leaving aside
whether they have taken notice of the contents of the official SPC in the first place.
It is recommended that the accessibility of SPCs for doctors and pharmacists is
enhanced, drawing attention specifically to any changes. All evidence-based
findings, including information obtained in clinical trials performed during the pre-
marketing stage (not just didactic statements), need to be made available. Greater
awareness about adverse drug reactions, regarding their significance, recognition,
management and prevention, needs to be established. In order to enhance the
knowledge of the effects of drugs in the clinical practice it is vital that doctors and
pharmacists report suspected adverse effects to their national pharmacovigilance
centres. These centres need to find effective ways to disseminate the data they have
collected to the various professional groups and should be involved in and
contribute to the education of health professionals. In short, there needs to be a
body of information for every drug that is available from a single accessible source.
There are numerous publications and websites that provide useful information but
they do not have regulatory approval. The Cochrane Foundation provides useful
reviewed information, but does not go far enough in factoring in knowledge other
than from controlled trials. As argued above, other material is essential to bridge the
gap between information from an ideal therapeutic situation and the application of
such knowledge in a difficult patient.
Publication in national Drug Bulletins and issuing notices on special websites
should be considered. In this context the US FDA has recently published proposals
regarding improvements of the SPC.(6) 
Doctors must make decisions on the relative effectiveness and risks of the
treatments they advise for their individual patients. There needs to be much more
thought about how to support this essential function. The UK’s National Institute
for Clinical Excellence (NICE) can be seen as a way forward in this respect, for the
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introduction of new therapies. NICE tackles the difficult issue of reconciling
relative effectiveness and cost; and issues guidelines, not mandates. A recent review
of its work so far was positive, although indicating that the magnitude of the tasks
facing NICE is great. The main challenge was seen as providing comprehensive
treatment guidelines into which context any new treatment must be fitted.(7)
Similar initiatives have been developed in the US (Centers for Education and
Research on Therapeutics) and The Netherlands (‘Standards’ of The Netherlands
Society of General Practitioners).
3. Communication
Communication is a two-way loop; one must ensure that information is received,
understood and acted upon correctly before a communication can be said to have
been successful.
There is much to be done in the area of communication, both in terms of follow-up
and understanding of health professionals’ behaviour and how to empower best
practise. In the Erice Report on drug safety information it is stated that ‘drug safety
information must serve the health of the public’.(8) The Erice Declaration also
commends the idea of actively communicating uncertainty. This is a difficult issue,
but in the safety area it has a good deal to recommend it because of the tentative
information about many even serious adverse drug reactions.
4. Professional Freedom and Professional Responsibility
Physicians and pharmacists have enjoyed great professional freedom. Given the
experiences already described, one needs to ensure that information and systems
support such freedom. This requires that more attention be given to the feedback
parts of the communication loop mentioned in section 3. More stringent
approaches need to be set in place to find out about deviations from SPCs. Off-label
prescriptions need to be documented and any adverse effects should be reported.
The impact of a change in the content of an SPC or a ‘Dear Doctor letter’ will be
greater when these conditions are fulfilled, since they will reflect rather than force
clinical practice.
4.4.5 Contribution of pharmacists
The dispensing pharmacist can play an important role in the implementation of
warnings and contraindications. Increasingly, pharmacists consider providing
pharmaceutical care a part of their professional responsibilities.(9) As with
prescription of drugs, dispensing drugs cannot be noncommittal. Pharmacies in
developed countries have sophisticated computer tools that help them monitor
drugs for known interactions, contraindications and other important information
contained in the SPC. To be able to monitor the indication for which the drug is
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being prescribed, the pharmacist needs to be informed of the physician’s indications
for prescribing the drug. In practice this is as yet rarely the case and many health
professionals object to providing this information. Jones et al. conclude in their
study that in 89% of the cases in which cisapride had been prescribed in
conjunction with a contraindicated drug, both drugs had been dispensed by one
and the same pharmacy.(1) Pharmacists need to be given a pivotal role in the
surveillance of the safe use of drugs.
4.4.6 Conclusion
Although careful attention is being paid to the contents of SPCs and ‘Dear Doctor’
letters it has become clear that this is not enough. There is a gap between the
determination of an SPC and daily practice. Creative, not a legalistic ways need to
be found that will fill that gap to the benefit of all concerned parties: professionals,
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